Key facts
as of Sep 2026- Angioinsight’s last known valuation is $18.0M (Jul 2024).
- It has raised $10.5M; the latest was Later Stage VC ($25.0M) in Jul 2025.
- Notable investors include US National Science Foundation, Innovation Partnerships, Avestria Ventures, Dakota Venture Group, Joyce and Don Massey Family Foundation — 6 tracked in total.
- 1 institutional filer reports fund marks on Angioinsight across 5 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Angioinsight
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Angioinsight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Apr 20261 SEC-registered fund reported 5 fair-value marks on Angioinsight between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Angioinsight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Angioinsight
Developer of artificial intelligence (AI) diagnostic tools designed to improve the detection and management of cardiovascular disease. The company's platform delivers real-time, image-based assessments of both anatomical and functional conditions, including coronary microvascular disease, enabling more accurate, efficient, and accessible care for patients and providers.
- Sector
- Healthcare
- HQ
- Minnetonka, MN, United States
- Founded
- 2013
- Website
- angioinsight.com/
- Ownership
- Privately Held (backing)